Allogene reports patient death tied to its CAR-T drug

The drugmaker said 3 out of 5 patients treated with a high-dose of the CAR-T therapy reacted to it; one patient showed a complete reaction; and another an excellent partial action..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

More posts on drug store: FDA customers appear to endorse Biogens Alzheimers drugAmericans have practically doubled costs on specialty drugs from pharmacies, study findsFDA, FTC warn 2 business offering defective COVID-19 treatments.

Allogene Therapeutics stated Nov. 4 that a person of its patients in a scientific trial for its numerous myeloma CAR-T drug died of fungal pneumonia.

In August, the FDA halted San Diego-based drugmaker Poseida Therapeutics medical trial of a CAR-T treatment after a client died of liver failure..

Allogene stated it will be launching more outcomes Dec. 5..

The client death is the most recent in a string of CAR-T-related deaths reported since July. That month, the FDA put a scientific hang on French drugmaker Cellectis trial for its off-the-shelf CAR-T therapy after a patient died of heart attack..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.

Investigators associated the pneumonia to the chemotherapy patients receive right before receiving CAR-T treatment. Experts were divided on how big a function the CAR-T drug played in the clients death and how worried to be if it is linked to the drug, according to Endpoints News..

The California-based biotech business likewise said that 4 patients contracted major infections. The client who passed away was detected with fungal pneumonia 8 days after receiving the CAR-T drug..

Maia Anderson –
Thursday, November 5th, 2020

In late October, an off-the-shelf CAR-T cell therapy being developed by CRISPR Therapeutics was likewise tied to a patients death..